FY2024 EPS Estimates for Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Increased by HC Wainwright

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM - Free Report) - Stock analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of Actinium Pharmaceuticals in a report released on Monday, April 29th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings of ($1.61) per share for the year, up from their previous forecast of ($1.94). HC Wainwright currently has a "Buy" rating and a $50.00 target price on the stock. The consensus estimate for Actinium Pharmaceuticals' current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals' Q2 2024 earnings at ($0.38) EPS, Q3 2024 earnings at ($0.45) EPS, Q4 2024 earnings at ($0.48) EPS and FY2025 earnings at $1.21 EPS.

Several other analysts have also issued reports on the company. Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday. StockNews.com upgraded Actinium Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Monday. Finally, Maxim Group upped their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a "buy" rating in a report on Tuesday, March 19th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $25.72.

Actinium Pharmaceuticals Stock Performance

NYSEAMERICAN:ATNM traded up $0.10 during mid-day trading on Wednesday, reaching $7.80. 227,254 shares of the company's stock were exchanged, compared to its average volume of 320,636. Actinium Pharmaceuticals has a one year low of $4.00 and a one year high of $9.86. The firm has a market cap of $232.28 million, a price-to-earnings ratio of -4.50 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM - Get Free Report) last posted its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.21. The firm had revenue of $0.08 million for the quarter.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Sanders Morris Harris LLC bought a new position in Actinium Pharmaceuticals in the 1st quarter valued at $78,000. Creative Financial Designs Inc. ADV raised its holdings in shares of Actinium Pharmaceuticals by 19.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company's stock valued at $101,000 after acquiring an additional 3,175 shares in the last quarter. Finally, Brandywine Global Investment Management LLC bought a new stake in shares of Actinium Pharmaceuticals during the 3rd quarter valued at about $1,033,000. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.